GISMO THERAPEUTICS INC.
Howard Beach, NY · Biotech · Private
Small molecule drug (GTC-3295) that inhibits amyloid-beta and tau protein interactions with heparan sulfate glycosaminoglycans to reduce neurodegeneration in Alzheimer's disease
- Grants
- $7.9M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy | $224,997 | |
| Federal grant | Department of Health and Human Services · Phase I · Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy | $224,997 | |
| Federal grant | Department of Health and Human Services · Phase I · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic | $241,938 | |
| Federal grant | Department of Health and Human Services · Phase I · Glycosaminoglycan Interacting Small Molecule GISMO as Parkinson s Therapeutic | $384,126 | |
| Federal grant | Department of Health and Human Services · Phase I · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic | $142,188 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics | $933,415 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics | $952,480 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease | $983,932 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease | $1,776,789 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease | $792,857 | |
| Federal grant | Department of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease | $1,192,768 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1707 | Remedy Labs, Inc. | — | $500K |
| 1708 | STOECKER MD, WILLIAM V | — | — |
| 1709 | MTI BIOTECH, INC. | — | — |
| 1710 | GISMO THERAPEUTICS INC. | — | — |
| 1711 | SINOPIA BIOSCIENCES INC | — | — |
| 1712 | NEUROGT INC | — | — |
| 1713 | Lila Sciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereofapplication
- Compounds And Pharmaceutical Compositions Comprising Inhibitors Of Amyloid Peptide Interactions With Glycosaminoglycans, Methods Of Treatment, And Use Thereofapplication
- Compounds And Pharmaceutical Compositions Comprising Inhibitors Of Amyloid Peptide Interactions With Glycosaminoglycans, Methods Of Treatment, And Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.